Global Health EDCTP3 JU Training Fellowship Programme

This Global Health EDCTP3 training fellowship programme will target early and mid-career African global health scientists seeking international academic credentials and other professional enrichment.

Scope

• Proposals submitted to this topic should implement a master’s level training programme in a discipline relevant for the Global Health EDCTP3 JU, providing transferable R&D skills, fostering innovation and entrepreneurship, incl. commercialisation of results, Intellectual Property Rights, communication, public engagement, and citizen science.
• The training provided by the academic institutions is expected to be complemented by training modules provided by pharmaceutical companies. It is expected that pharmaceutical companies will join the consortium as beneficiaries and/or associated partners at a later stage. The companies are expected to bring cash or in-kind contributions to the training programme for the fellows.
• Proposals must demonstrate all of the following:
  • A high-quality training programme related to R&D on diseases in the scope of the Global Health EDCTP3 JU at master level in global health/clinical research;
  • An open, fair and transparent procedure for selecting the fellows coming from different geographical regions of SSA, based on quality and with appropriate gender balance;
  • Design of a programme where training for each fellow includes a first phase (or outgoing phase) of minimum 12 and maximum 24 months’ enrolment into an academic organization, and a second phase (or return phase) of at least 12 months in the country of origin of the fellow;
  • A robust training and mentorship mechanisms to support the fellows through their first training phase and second home return phase;
  • Linkages with other Global Health EDCTP3 JU actions should be foreseen as relevant (e.g. Global Health EDCTP3 Training Networks or Global Health EDCTP3 Genomic Epidemiology Networks).

Funding Information

• The check will normally be done for the coordinator if the requested grant amount is equal to or greater than EUR 500 000, except for:
  • public bodies (entities established as a public body under national law, including local, regional or national authorities) or international organisations; and
  • cases where the individual requested grant amount is not more than EUR 60 000 (low value grant).

Expected Outcomes

• Project results are expected to contribute to the following outcomes:
  • Foster the culture of pharmaceutical innovation and entrepreneurship in sub-Saharan Africa;
  • Increase the number of skilled clinical researchers and innovators in sub-Saharan Africa;
  • Promote the career development and retention of skilled personnel in sub-Saharan Africa;
  • Strengthen sub-Saharan African countries clinical human capital base in Research and Innovation (R&I);
  • Enhance talent retention, knowledge circulation and uptake across the research and innovation landscape in sub-Saharan Africa;
  • Establish sustainable and mutually beneficial collaboration between clinical research organisations, academia, and Industry Partners across sub-Saharan Africa and Europe.

Eligible Activities

• Projects must focus exclusively on civil applications and must not:
  • aim at human cloning for reproductive purposes;
  • intend to modify the genetic heritage of human beings which could make such changes heritable (except for research relating to cancer treatment of the gonads, which may be financed);
  • intend to create human embryos solely for the purpose of research, or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer.
• Projects must, moreover, comply with EU policy interests and priorities (environment, social, security, industrial policy, etc.).
• The following activities are generally eligible for grants under Horizon Europe:
  • Research and innovation actions (RIA) — Activities that aim primarily to establish new knowledge or to explore the feasibility of a new or improved technology, product, process, service or solution. This may include basic and applied research, technology development and integration, testing, demonstration and validation of a small-scale prototype in a laboratory or simulated environment.
  • Innovation actions (IA) — Activities that aim directly to produce plans and arrangements or designs for new, altered or improved products, processes or services. These activities may include prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.
  • Coordination and support actions (CSA) — Activities that contribute to the objectives of Horizon Europe. This excludes research and innovation (R&I) activities, except those carried out under the ‘Widening participation and spreading excellence’ component of the programme (part of ‘Widening participation and strengthening the European Research Area’).
  • Programme co-fund actions (CoFund) — A programme of activities established or implemented by legal entities managing or funding R&I programmes, other than EU funding bodies.
  • Innovation and market deployment actions (IMDA) — Activities that embed an innovation action and other activities necessary to deploy an innovation on the market. This includes the scaling-up of companies and Horizon Europe blended finance.
  • Training and mobility actions (TMA) — Activities that aim to improve the skills, knowledge and career prospects of researchers, based on mobility between countries and, if relevant, between sectors or disciplines.
  • Pre-commercial procurement actions (PCP) — Activities that aim to help a transnational buyers’ group to strengthen the public procurement of research, development, validation and, possibly, the first deployment of new solutions that can significantly improve quality and efficiency in areas of public interest, while opening market opportunities for industry and researchers active in Europe.

Eligibility Criteria

• Entities eligible for funding
  • To be eligible for funding, applicants must be established in one of the following countries:
    • the Member States of the European Union, including their outermost regions:
      • Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.
    • the Overseas Countries and Territories (OCTs) linked to the Member States:
      • Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR).
    • countries associated to Horizon Europe:
      • Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine.
• Specific cases
  • Affiliated entities — Affiliated entities are eligible for funding if they are established in one of the countries listed above, or in a country identified in the specific call conditions.
  • Associated partners — Entities not eligible for funding (and therefore not able to participate as beneficiaries) may participate as associated partners, unless specified otherwise in the specific call conditions.
  • Coordination and Support Actions – To be eligible to participate as beneficiaries (or affiliated entities) in ‘Coordination and support’ actions, legal entities must be established in a Member State or Associated Country, unless the specific call conditions provide otherwise.
  • EU bodies — Legal entities created under EU law may also be eligible to receive funding, unless their basic act states otherwise.
  • International organisations — International European research organisations are eligible to receive funding. Unless their participation is considered essential for implementing the action by the granting authority, other international organisations are not eligible to receive funding.

For more information, visit EC.